On heels of an IPO, Concert’s kidney drug flops in PhII

John Carroll

Just two months after raising $ 84 million from an upsized IPO, Concert Pharmaceuticals says that a key Phase II study of its lead –CTP-499–flopped on its primary endpoint for diabetic disease.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS